Synergy of flavone with vancomycin and oxacillin against vancomycin-intermediate Staphylococcus aureus

Pakistan Journal of Pharmaceutical Sciences

Volumn 25, Issue 3, 2012, Pages 633-638

  Bakar, Nur Salwani ^a   Zin, Noraziah Mohamad ^a   Basri, Dayang Fredalina ^a  

^a UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

Author keywords

Flavonoid; Oxacillin; Vancomycin; VISA

Indexed keywords

3,7 DIHYDROXYFLAVONE; AURANTIIN; FISETIN; FLAVONE; FLAVONOID; HESPERETIN; HESPERIDIN; NARINGENIN; OXACILLIN; QUERCETIN; RUTOSIDE; UNCLASSIFIED DRUG; VANCOMYCIN;

ARTICLE; BACTERIAL GROWTH; CONCENTRATION RESPONSE; DRUG ACTIVITY; DRUG POTENTIATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; DRUG COMBINATIONS; DRUG SYNERGISM; FLAVONOIDS; MICROBIAL SENSITIVITY TESTS; OXACILLIN; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 84863449152     PISSN: 1011601X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Bierbaum G, Fuchs K, Lenz W, Szekat C and Sahl H-G (1999). Presence of Staphylococcus aureus with reduced susceptibility to vancomycin in Germany. Eur. J. Clin. Microbiol. Infect. Dis., 18: 691-696. (Pubitemid 29537446)
2. Centers for Disease Control and Prevention (CDC) (1996). National Nosocomial Infections Surveillance report, data summary from October 1986-April 1996, issued May 1996. Am. J. Infect. Control, 24: 380-388.
3. Craig WA and Gudmundsson S (1986). The postantibiotic effect. In: Lorian V (editor). Antibiotics in laboratory medicine. 2nd ed. The Williams & Wilkins Co., Baltimore, Md: pp.515-536.
4. da Silva LV, Araújo MT, dos Santos KRN and Nunes APF (2011). Evaluation of the synergistic potential of vancomycin combined with other antimicrobial agents against methicillin-resistant Staphylococcus aureus and coagulase-negative Staphylococcus spp. strains. Memorias do Institute Oswaldo Cruz., 106(1): 44-50.
5. Domaracki, BE, Evans AM and Venezia RA (2000). Vancomycin and Oxacillin Synergy for Methicillin- Resistant Staphylococci. Antimicrob. Agents Chemother., 44: 1394-1396. (Pubitemid 30228332)
6. Ermertcan S, Hoşgör-Limoncu M, Taşli H, Çilli F and Coşar G (2010). In vitro activity of linezolid in combination with vancomycin, teicoplanin, fusidic acid, and ciprofloxacin against gram-positive pathogens. Turk. Klin. Tip. Bilim., 30(1): 711-714.
7. Hadji-Nejad S, Rahbar M and Mehrgan H (2010). Synergy between phenothiazines and oxacillin against clinical isolates of methicillin-resistant Staphylococcus aureus. Trop. J. Pharm. Res., 9(3): 243-249.
8. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T and Tenover FC (1997). Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother., 40: 135-136. (Pubitemid 27341646)
9. Howe RA, Bowker KE, Walsh T, Feest TG and MacGowan AP (1998). Vancomycin-resistant Staphylococcus aureus. Lancet, 351: 602.
10. LaPlante KL (2007). In vitro activity of lysostaphin, mupirocin, and tea tree oil against clinical methicillin-resistant Staphylococcus aureus. Diagn. Microbiol. Infect. Dis., 57: 413-418.
11. LaPlante KL and Rybak MJ (2004). Clinical glycopeptide-intermediate staphylococci tested against arbekacin, daptomycin, and tigecycline. Diagn. Microbiol. Infect. Dis., 50: 125-130.
12. Lewis K and Ausubel F (2006). Prospects for plant-derived antibacterial. Nat. Biotechnol., 24(12): 1504-1507.
13. Lowy FD (1998). Staphylococcus aureus infections. N. Engl. J. Med., 339: 520-532.
14. National Committee for Clinical Laboratory Standards (NCCLS) (2004). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 5th ed., Approved standard, M7-A6. Wayne, Pennsylvania: National Committee for Clinical Laboratory Standards.
15. Ploy MC, Grelaud C, Martin C, deLumley L and Denis F (1998). First clinical isolate of vancomycinintermediate Staphylococcus aureus in a French hospital. Lancet, 351: 1212. (Pubitemid 28171844)
16. Rand KH and Houck H (2004). Synergy of daptomycin with oxacillin and other B-lactams against methicillin- resistant Staphylococcus aureus. Antimicrob. Agents Chemother., 48(8): 2871-2875. (Pubitemid 38989149)
17. Rotun SS, McMath V, KShoonmarker DJ, Maupin PS, Tenover FC and Hill BC (1999). Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. Emerg. Infect. Dis., 5(1): 147-149. (Pubitemid 29124786)
18. Sato Y, Shibata H, Arakaki N and Higuti T (2004). 6,7-dihydroxyflavone dramatically intensifies the susceptibility of methicillin-resistant or - sensitive Staphylococcus aureus to B-Lactams. Antimicrob. Agents Chemother., 48(4): 1357-1360. (Pubitemid 38405495)
19. th ed., Churchill Livingstone, New York, pp.1754-1777.